Synexus starts up in South Africa

By Kirsty Barnes

- Last updated on GMT

Related tags: Clinical trials, Clinical trial, Clinical research, Synexus

UK-based Synexus Clinical Research is continuing its global
movements with the latest acquisition of South African outfit
Clinical Research Centers (CRC).

The firm said it plans to buy the Site Management Organisation (SMO), which specialises in the same area as Synexus - patient recruitment for late-stage clinical trials - for an amount between £810,000 and £980,000.

Addclin carries out bioequivalence and pharmacokinetic studies for South African and international generics companies and Synexis said that this part of the acquisition "is exciting as it is not only provides a link with a large multinational healthcare company but is also a low risk entry into the early stage market."

In addition, this is the firm's first foray into the Southern Hemisphere and "represents a further opportunity for the company to exploit the growing clinical trials and patient recruitment markets in emerging economies."

The purchase is also another step in Synexus' stated strategy is to build a multi-country operation - a strategy that is has been pursuing enthusiastically since joining AIM in November 2005.

In June the company bagged Hungarian company, Diagnostic Units Hungary (DUH), and bought Polish clinical trials company Skandynawskie Centrum Medyczne (SCM) in January in a bid to exploit the growing clinical trial opportunities in the emerging Eastern European market.

Related topics: Clinical Development, Phase III-IV

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars